Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cyprotex Acquires CeeTox

Published: Thursday, January 02, 2014
Last Updated: Thursday, January 02, 2014
Bookmark and Share
Auquistion broadens toxicological assay and screening capabilities to the cosmetic and personal care industry.

Cyprotex PLC announces the acquisition of the business and assets of CeeTox, Inc, a division of North American Science Associates, Inc.

CeeTox, based in Kalamazoo, MI, USA, is a Contract Research Organisation specialising in the provision of in vitro toxicological assays and screening data, principally to the Cosmetic and Personal Care Industries. Founded in 2003, CeeTox was acquired in 2005 by NAMSA, a medical research organisation supplying expert consulting, clinical and laboratory services to medical device, IVD and biologics manufacturers. NAMSA retains a license for applying CeeTox’s in vitro toxicology expertise to medical device testing. CeeTox had sales of approximately £2.3 million in the year ended 30 September 2013 and made an operating loss of approximately £0.9 million. The initial consideration for the purchase of £0.63 million is funded by internal cash resources, with a further consideration of 5% payable on specified net sales achieved in the next four years to a maximum of £3.1 million. The purchase is made by the group’s US trading subsidiary, Apredica, LLC. The impact of the acquisition is expected to be earnings neutral in the first year.

It is expected that Cyprotex will continue to operate the CeeTox business from its Kalamazoo location for a period of time prior to relocation of the business and assets to Cyprotex’s US base in Watertown, MA.

Commenting on the acquisition, Dr Anthony Baxter, CEO of Cyprotex, said: “The acquisition of CeeTox and its world-respected in vitro toxicology assays affords Cyprotex the opportunity to grow revenues significantly. Principally, it enables the Company to offer a more complete assay and screening service to the Cosmetics and Personal Care Industry, already an expanding customer segment, and will materially extend the Company’s footprint in its established core Pharmaceutical and Agrochemical industry markets.

“The innovative assays and screens that CeeTox has developed over its 10-year life are complementary to our existing comprehensive platform. In particular, we are excited by the potential for selling the Endocrine Disruptor Screening Programme (EDSP) service to both current Government agency customers and to industrial chemical companies.”

Mr. Tim Mitchell, CEO of CeeTox, added: “We are delighted that, in acquiring the CeeTox business, Cyprotex is committed to both maintaining our reputation for innovative high quality science and to growing our existing customer base. The combination of our two businesses represents an outstanding opportunity to leverage our capabilities and capitalise on the enormous market potential across a variety of industries that require in vitro toxicity screening services.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cyprotex Appoints Dr Rob Elsby as Leader of Drug Transporter Team
Cyprotex PLC has appointed Dr Rob Elsby as Leader of its Drug Transporter Team.
Wednesday, March 18, 2015
Cyprotex Announces a Collaborative Research Agreement with Pfizer
The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved.
Friday, November 02, 2012
Cyprotex Launch Updated Drug-Drug Interaction Regulatory Guidance
Booklet to reflect the new FDA and EMA guidelines.
Friday, August 17, 2012
Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance
The companies have announced they have entered into an extension of their highly successful partnership for a further 2 years.
Monday, December 19, 2011
Cyprotex Extends Cloe® Screen Mechanism-Based Inhibition Service to Include 4 Additional Cytochrome P450 Isoforms
New assays compliment the CYP3A4 isoform assay which was launched last year.
Friday, March 30, 2007
Scientific News
How Cancer Spreads in the Body
Cancer cells appear to depend on an unusual survival mechanism to spread around the body, according to an early study led by Queen Mary University of London.
Rates of Nonmedical Prescription Opioid Use Disorder Double in 10 Years
Researchers at NIH have found that the nonmedical use of prescription opioids has more than doubled among adults in the United States from 2001-2002 to 2012-2013.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
‘Human-on-a-Chip’ Could Replace Animal Testing
Researchers are developing a “human-on-a-chip,” a miniature external replication of the human body, integrating biology and engineering with a combination of microfluidics and multi-electrode arrays.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
‘Missing Tooth’ Hydrogels Handle Hard-to-Deliver Drugs
Rice University’s custom hydrogel traps water-avoiding molecules for slow delivery.
Copper is Key in Burning Fat
Berkeley Lab scientist says results could provide new target for obesity research.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!